PMID- 32361653
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 84
DP  - 2020 Jul
TI  - The protective effect of myricitrin in osteoarthritis: An in vitro and in vivo 
      study.
PG  - 106511
LID - S1567-5769(19)32369-0 [pii]
LID - 10.1016/j.intimp.2020.106511 [doi]
AB  - Osteoarthritis (OA) is a long-term, chronic, progressive joint condition caused 
      by a pathology characterized by the deterioration of joint cartilage and 
      proliferation of subchondral bone. Myricitrin (Myr) is a flavonoid compound 
      extracted from myrica rubra with potent anti-inflammatory properties, as 
      demonstrated in various studies. However, the mechanisms by which Myr plays a 
      protective role in OA are not completely understood. In this study, the 
      anti-inflammatory properties and potential mechanisms of Myr on mouse 
      chondrocytes treated with interleukin (IL) -1beta (beta) were explored in vitro and 
      the role of Myr in a mouse model of OA in vivo. The production of 
      pro-inflammatory factors, such as IL-6, tumor necrosis factor alpha (TNF-alpha), 
      prostaglandin E2 (PGE2) and nitric oxide (NO) were assessed by enzyme linked 
      immunosorbent assay (ELISA) and the Griess reaction. Protein expression of 
      inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), Collagen-II, 
      matrix metalloproteinase(MMP)-13, MMP-3, thrombospondin motifs 5(ADAMTS5), 
      inhibitor ofnuclear factor kappa-B (IkappaB), p-IkappaB, p65, p-p65, c-jun-terminal 
      kinase (JNK), p-JNK, extracellular regulated protein kinases (ERK), p-ERK, p38 
      and p-p38 were quantified using Western blot analysis. In the present study, we 
      found that Myr inhibited IL-1beta-induced production of NO and PGE2, expression of 
      MMP-13, MMP-3 and ADAMTS5 and degradation of collagen-II in mouse chondrocytes. 
      Mechanistically, Myr inhibited the activation of mitogen-activated protein kinase 
      (MAPK) and nuclear factor kappa-B (NF-kappaB) treated with IL-1beta in mouse 
      chondrocytes. In vivo, Myr decreased OA Research Society International (OARSI) 
      scores in a surgically-induced mouse model of OA. These data suggest that Myr 
      could be developed as a potential therapyfor OA.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Yan, Zijian
AU  - Yan Z
AD  - Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China; 
      Zhejiang Provincial Key Laboratory of Orthpaedics, Wenzhou 325000, Zhejiang 
      Provinece, China; The Second School of Medicine, WenZhou Medical University, 
      Wenzhou, 325000 Zhejiang Province, China.
FAU - Lin, Zeng
AU  - Lin Z
AD  - Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China; 
      Zhejiang Provincial Key Laboratory of Orthpaedics, Wenzhou 325000, Zhejiang 
      Provinece, China; The Second School of Medicine, WenZhou Medical University, 
      Wenzhou, 325000 Zhejiang Province, China.
FAU - Wu, Yifan
AU  - Wu Y
AD  - Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China; 
      Zhejiang Provincial Key Laboratory of Orthpaedics, Wenzhou 325000, Zhejiang 
      Provinece, China; The Second School of Medicine, WenZhou Medical University, 
      Wenzhou, 325000 Zhejiang Province, China.
FAU - Zhan, Jingdi
AU  - Zhan J
AD  - Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China; 
      Zhejiang Provincial Key Laboratory of Orthpaedics, Wenzhou 325000, Zhejiang 
      Provinece, China; The Second School of Medicine, WenZhou Medical University, 
      Wenzhou, 325000 Zhejiang Province, China.
FAU - Qi, Weihui
AU  - Qi W
AD  - Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China; 
      Zhejiang Provincial Key Laboratory of Orthpaedics, Wenzhou 325000, Zhejiang 
      Provinece, China; The Second School of Medicine, WenZhou Medical University, 
      Wenzhou, 325000 Zhejiang Province, China.
FAU - Lin, Jian
AU  - Lin J
AD  - Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China; 
      The Second School of Medicine, WenZhou Medical University, Wenzhou, 325000 
      Zhejiang Province, China.
FAU - Shen, Jiquan
AU  - Shen J
AD  - The Second School of Medicine, WenZhou Medical University, Wenzhou, 325000 
      Zhejiang Province, China; Department of Orthopaedics, Lishui Municipal People 
      Hospital, Lishui 323000, Zhejiang Province, China.
FAU - Xue, Xinghe
AU  - Xue X
AD  - Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China. 
      Electronic address: qq524689473@163.com.
FAU - Pan, Xiaoyun
AU  - Pan X
AD  - Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's 
      Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China. 
      Electronic address: panxy9046@163.com.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Flavonoids)
RN  - 0 (NF-kappa B)
RN  - 5Z0ZO61WPJ (myricitrin)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.13.39 (Nos2 protein, mouse)
RN  - EC 1.14.99.- (Ptgs2 protein, mouse)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 3.4.24.- (ADAMTS5 Protein)
RN  - EC 3.4.24.- (Matrix Metalloproteinase 13)
RN  - EC 3.4.24.- (Mmp13 protein, mouse)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - EC 3.4.24.17 (Mmp3 protein, mouse)
SB  - IM
MH  - ADAMTS5 Protein/metabolism
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Cells, Cultured
MH  - Chondrocytes/drug effects/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Extracellular Matrix/drug effects
MH  - Flavonoids/pharmacology/*therapeutic use
MH  - Knee Joint/drug effects/pathology
MH  - Male
MH  - Matrix Metalloproteinase 13/metabolism
MH  - Matrix Metalloproteinase 3/metabolism
MH  - Mice, Inbred C57BL
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - NF-kappa B/metabolism
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Osteoarthritis/*drug therapy/metabolism/pathology
OTO - NOTNLM
OT  - IL-1beta
OT  - Inflammation
OT  - MAPK
OT  - Myricitrin
OT  - NF-kappaB
COIS- Declaration of Competing Interest The authors declare that they have no conflicts 
      of interest.
EDAT- 2020/05/04 06:00
MHDA- 2021/03/11 06:00
CRDT- 2020/05/04 06:00
PHST- 2019/10/19 00:00 [received]
PHST- 2020/04/11 00:00 [revised]
PHST- 2020/04/12 00:00 [accepted]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
PHST- 2020/05/04 06:00 [entrez]
AID - S1567-5769(19)32369-0 [pii]
AID - 10.1016/j.intimp.2020.106511 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2020 Jul;84:106511. doi: 10.1016/j.intimp.2020.106511. Epub 
      2020 May 1.